Nachrichten zur Editas Medicine Aktie

Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates

Commenced parallel patient dosing in the EDIT-301 RUBY trial for SCD, following clinical proof-of-concept demonstrated last quarter...…

Editas Medicine Q4 2022 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Is Exact Sciences or Editas Medicine the Better Growth Stock to Own in 2023?

Which of these rebounding biotech stocks is the better buy right now?...…

Insiderhandel: EVP, CBO AND CTO verkauft Aktien von Editas Medicine im Wert von 31.963$

Eaton, Bruce - Vorstand - Tag der Transaktion: 2023-02-13...…

Insiderhandel: EVP, CHIEF SCIENTIFIC OFFICER verkauft Aktien von Editas Medicine im Wert von 26.966$

Shearman, Mark S. - Vorstand - Tag der Transaktion: 2023-02-13...…

Insiderhandel: EVP, CHIEF FINANCIAL OFFICER verkauft Aktien von Editas Medicine im Wert von 41.435$

Robertson, Michelle - Vorstand - Tag der Transaktion: 2023-02-13...…

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update

CAMBRIDGE, Mass., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing…

Does Editas (EDIT) Have the Potential to Rally 51.55% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 51.6% in Editas (EDIT). While…

Is Editas Medicine Stock a Buy Now?

Layoffs and a thin clinical-stage pipeline arent very encouraging....…

Why Editas Medicine Stock Charged Higher in January

The genome-editing companys shares spiked following a definitive agreement with Shoreline Biosciences last month....…

Editas, Beam win bullish views as Cantor launches gene editing coverage

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Editas Medicine (EDIT) Crossed Above the 50-Day Moving Average: What That Means for Investors

Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?...…

Why Shares of Editas Medicine Jumped This Week

Its been a seesaw month for the clinical-stage gene-editing biotech....…

Editas (EDIT) Moves Ahead With its Portfolio Reprioritization

Editas (EDIT) enters into a deal with Shoreline Biosciences for licensing Editas proprietary gene editing technologies and cell franchise....…

Editas to sell natural killer cell programs to Shoreline

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Editas (EDIT) Dips on Portfolio Reprioritization, To Cut Jobs

Editas (EDIT) enters a restructuring and portfolio reprioritization to focus on hemoglobinopathies and in vivo gene editing. The company is…

Why Editas Medicine Stock Is Sliding Today

The gene-editing pioneer announced a big shake-up with its research and development programs....…

Editas Medicine tumbles more than 7% after announcing job cuts, restructuring

Editas Medicine Inc. [s: edit] is cutting approximately 20% of its workforce. The company reported 1,800 employees as of May…

Editas Medicine Shares Hit 52-Week Low After Reorganization, Layoffs

Editas Medicine Shares Hit 52-Week Low After Reorganization, Layoffs...…

Editas cuts 20% staff in portfolio overhaul

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K Editas Medicine, Inc. For: Jan 07

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Editas Medicine Announces Strategic Updates and Portfolio Reprioritization

Strategic reprioritization of portfolio to focus on hemoglobinopathies and in vivo gene editing...…

Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing…

Editas adds 12% after initial data for sickle cell disease candidate

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K Editas Medicine, Inc. For: Dec 06

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease

EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant...…

Why Shares of Editas Medicine Dropped 15.5% in November

The biotechs shares plummeted after it paused a key clinical trial....…

Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease

CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today…

dpa-AFX ProFeed